Three-Dimensional Surface Reconstruction for Specular/Diffuse Composite Surfaces.

This paper presents an effective three-dimensional (3D) surface reconstruction technique aimed at profiling composite surfaces with both specular and diffuse reflectance. Three-dimensional measurements based on fringe projection techniques perform well on diffuse reflective surfaces; however, when the measurement targets contain both specular and diffuse components, the efficiency of fringe projection decreases. To address this issue, the proposed technique integrates digital holography into the fringe projection setup, enabling the simultaneous capture of both specular and diffuse reflected light in the same optical path for full-field surface profilometry.

Sensitivity and Specificity of Three Measures of Intrinsic Capacity in Older People Aged 80 and Over in Nursing Homes.

Purpose: Intrinsic capacity (IC), a crucial indicator for the United Nations Decade of Healthy Ageing 2021-2030, is defined by WHO as the foundation of functional ability, representing the composite of all physical and mental capacities of an individual. IC spans five function domains: Locomotor, psychological, cognitive, vitality, and sensory (including vision and hearing). Accurate IC assessment is vital for effective interventions, yet comparative analyses of these tools are scarce.

Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for -Mutated NSCLC After Complete Resection.

Introduction: EGFR tyrosine kinase inhibitor (TKI) is the standard adjuvant treatment for patients with stages IB to IIIA -mutated NSCLC. Nevertheless, adapting this approach to include a molecular residual disease (MRD)-guided de-escalation strategy warrants further investigation.

Methods: From January 2019 to December 2022, 71 patients with stages I to III NSCLC and (exon 19 deletion or L858R) mutations were enrolled in this observational study.

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).

Background: The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment.

Methods: We conducted an open-label, single-arm, multicenter, phase II trial in China. Eligible patients were 18-75 years old with histologically or cytologically confirmed NSCLC who were EGFR mutation positive and showed gradual, oligo, or potential progression after EGFR-TKIs.